Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigations

Interim 18F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients

Cédric Rossi, Salim Kanoun, Alina Berriolo-Riedinger, Inna Dygai-Cochet, Olivier Humbert, Caroline Legouge, Marie Lorraine Chrétien, Jean-Noel Bastie, François Brunotte and René-Olivier Casasnovas
Journal of Nuclear Medicine April 2014, 55 (4) 569-573; DOI: https://doi.org/10.2967/jnumed.113.130609
Cédric Rossi
1Hématologie Clinique, CHU Le Bocage, Dijon, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salim Kanoun
2Médecine Nucléaire, Centre G.F. Leclerc, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alina Berriolo-Riedinger
2Médecine Nucléaire, Centre G.F. Leclerc, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inna Dygai-Cochet
2Médecine Nucléaire, Centre G.F. Leclerc, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Humbert
2Médecine Nucléaire, Centre G.F. Leclerc, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Legouge
1Hématologie Clinique, CHU Le Bocage, Dijon, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Lorraine Chrétien
1Hématologie Clinique, CHU Le Bocage, Dijon, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Noel Bastie
1Hématologie Clinique, CHU Le Bocage, Dijon, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Brunotte
2Médecine Nucléaire, Centre G.F. Leclerc, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
René-Olivier Casasnovas
1Hématologie Clinique, CHU Le Bocage, Dijon, France; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 55 no. 4 569-573
DOI 
https://doi.org/10.2967/jnumed.113.130609
PubMed 
24566003

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication August 6, 2013
  • Accepted for publication October 18, 2013
  • Published online April 1, 2014.

Article Versions

  • previous version (February 24, 2014 - 05:42).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Cédric Rossi1,
  2. Salim Kanoun2,
  3. Alina Berriolo-Riedinger2,
  4. Inna Dygai-Cochet2,
  5. Olivier Humbert2,
  6. Caroline Legouge1,
  7. Marie Lorraine Chrétien1,
  8. Jean-Noel Bastie1,
  9. François Brunotte2 and
  10. René-Olivier Casasnovas1
  1. 1Hématologie Clinique, CHU Le Bocage, Dijon, France; and
  2. 2Médecine Nucléaire, Centre G.F. Leclerc, Dijon, France
  1. For correspondence or reprints contact: René-Olivier Casasnovas, Hématologie Clinique, Hôpital Le Bocage–CHU Dijon, 10 Bd. de Lattre de Tassigny, 21079 Dijon Cedex, France. E-mail: olivier.casasnovas{at}chu-dijon.fr
View Full Text

Statistics from Altmetric.com

Cited By...

  • 65 Citations
  • 74 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
    A. Patnaik, L.J. Appleman, A.W. Tolcher, K.P. Papadopoulos, M. Beeram, D.W. Rasco, G.J. Weiss, J.C. Sachdev, M. Chadha, M. Fulk, S. Ejadi, J.M. Mountz, M.T. Lotze, F.G.S. Toledo, E. Chu, M. Jeffers, C. Peña, C. Xia, S. Reif, I. Genvresse, R.K. Ramanathan
    Annals of Oncology 2016 27 10
  • Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma
    Salim Kanoun, Cédric Rossi, Alina Berriolo-Riedinger, Inna Dygai-Cochet, Alexandre Cochet, Olivier Humbert, Michel Toubeau, Emmanuelle Ferrant, François Brunotte, René-Olivier Casasnovas
    European Journal of Nuclear Medicine and Molecular Imaging 2014 41 9
  • Imaging for Staging and Response Assessment in Lymphoma
    Sarah A. Johnson, Anita Kumar, Matthew J. Matasar, Heiko Schöder, Jürgen Rademaker
    Radiology 2015 276 2
  • Metabolic Tumor Volume Metrics in Lymphoma
    Lale Kostakoglu, Stéphane Chauvie
    Seminars in Nuclear Medicine 2018 48 1
  • FDG PET/CT imaging as a biomarker in lymphoma
    Michel Meignan, Emmanuel Itti, Andrea Gallamini, Anas Younes
    European Journal of Nuclear Medicine and Molecular Imaging 2015 42 4
  • Critical parameters in targeted drug development: the pharmacological audit trail
    Udai Banerji, Paul Workman
    Seminars in Oncology 2016 43 4
  • The role of PET/CT in the modern treatment of Hodgkin lymphoma
    Jan Maciej Zaucha, Stephane Chauvie, Renata Zaucha, Alberto Biggii, Andrea Gallamini
    Cancer Treatment Reviews 2019 77
  • Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients
    Anne-Ségolène Cottereau, Tarec Christoffer El-Galaly, Stéphanie Becker, Florence Broussais, Lars Jelstrup Petersen, Christophe Bonnet, John O. Prior, Hervé Tilly, Martin Hutchings, Olivier Casasnovas, Michel Meignan
    Journal of Nuclear Medicine 2018 59 4
  • Prognostic value of interim FDG‐PET in Hodgkin lymphoma: systematic review and meta‐analysis
    Hugo J. A. Adams, Rutger A. J. Nievelstein, Thomas C. Kwee
    British Journal of Haematology 2015 170 3
  • Prospective Study of 3′-Deoxy-3′-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma
    Heiko Schöder, Andrew D. Zelenetz, Paul Hamlin, Somali Gavane, Steven Horwitz, Matthew Matasar, Alison Moskowitz, Ariela Noy, Lia Palomba, Carol Portlock, David Straus, Ravinder Grewal, Jocelyn C. Migliacci, Steven M. Larson, Craig H. Moskowitz
    Journal of Nuclear Medicine 2016 57 5

Article usage

Article usage: February 2014 to April 2025

AbstractFullPdf
Feb 2014351064
Mar 2014282050
Apr 2014113031107
May 20143632256
Jun 20141691625
Jul 20141071532
Aug 20141331534
Sep 2014972627
Oct 20141153358
Nov 2014444162
Dec 2014582791
Jan 2015523660
Feb 2015403159
Mar 2015712464
Apr 2015552035
May 2015603038
Jun 2015202113
Jul 2015211114
Aug 2015622613
Sep 2015342721
Oct 2015281113
Nov 2015392634
Dec 2015502310
Jan 2016533124
Feb 2016432816
Mar 2016261919
Apr 2016212024
May 2016311826
Jun 201635187
Jul 2016361616
Aug 2016193223
Sep 2016292421
Oct 2016352117
Nov 2016242322
Dec 2016211515
Jan 2017292414
Feb 20171695
Mar 2017302316
Apr 201712116
May 2017191511
Jun 201716107
Jul 20171045
Aug 2017121510
Sep 201718144
Oct 2017221916
Nov 201718810
Dec 2017201613
Jan 201817118
Feb 201820810
Mar 2018211311
Apr 20181989
May 201817146
Jun 2018262110
Jul 201817176
Aug 201815145
Sep 201813149
Oct 2018191613
Nov 2018131921
Dec 2018191514
Jan 201918175
Feb 201924165
Mar 2019302611
Apr 2019223515
May 201912611
Jun 20191045
Jul 201922158
Aug 20191398
Sep 2019974
Oct 2019949
Nov 20196104
Dec 2019834
Jan 20201277
Feb 2020131013
Mar 20201059
Apr 202017310
May 2020151012
Jun 202018410
Jul 20201359
Aug 2020895
Sep 20207127
Oct 20201873
Nov 202018154
Dec 20206128
Jan 20212712
Feb 2021112313
Mar 202195114
Apr 202183910
May 20215277
Jun 20218224
Jul 202132818
Aug 202142815
Sep 202162013
Oct 202172128
Nov 202161221
Dec 20215207
Jan 20226166
Feb 20227187
Mar 202292312
Apr 202221914
May 202222618
Jun 202241912
Jul 20223205
Aug 202232111
Sep 2022102111
Oct 202291910
Nov 202232810
Dec 20223246
Jan 202354216
Feb 20232112
Mar 20235207
Apr 2023392
May 20231168
Jun 20230208
Jul 20232125
Aug 202371213
Sep 2023293
Oct 20236149
Nov 20232118
Dec 20230296
Jan 20247319
Feb 20241185
Mar 202402242
Apr 2024123626
May 202442714
Jun 20243328
Jul 202456510
Aug 202455919
Sep 202455213
Oct 2024102516
Nov 20242265
Dec 202412510
Jan 20252337
Feb 20251558
Mar 202545326
Apr 2025104531
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 55 (4)
Journal of Nuclear Medicine
Vol. 55, Issue 4
April 1, 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Interim 18F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Interim 18F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients
Cédric Rossi, Salim Kanoun, Alina Berriolo-Riedinger, Inna Dygai-Cochet, Olivier Humbert, Caroline Legouge, Marie Lorraine Chrétien, Jean-Noel Bastie, François Brunotte, René-Olivier Casasnovas
Journal of Nuclear Medicine Apr 2014, 55 (4) 569-573; DOI: 10.2967/jnumed.113.130609

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Interim 18F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients
Cédric Rossi, Salim Kanoun, Alina Berriolo-Riedinger, Inna Dygai-Cochet, Olivier Humbert, Caroline Legouge, Marie Lorraine Chrétien, Jean-Noel Bastie, François Brunotte, René-Olivier Casasnovas
Journal of Nuclear Medicine Apr 2014, 55 (4) 569-573; DOI: 10.2967/jnumed.113.130609
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients
  • Response Assessment Criteria and Their Applications in Lymphoma: Part 2
  • Comparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy
  • Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma
  • Google Scholar

More in this TOC Section

  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
  • An Investigation of Lesion Detection Accuracy for Artificial Intelligence–Based Denoising of Low-Dose 64Cu-DOTATATE PET Imaging in Patients with Neuroendocrine Neoplasms
Show more Clinical Investigations

Similar Articles

Keywords

  • interim PET
  • 18F-FDG PET
  • Hodgkin lymphoma
  • SUVmax
  • 5-point scale
SNMMI

© 2025 SNMMI

Powered by HighWire